Latest & greatest articles for colorectal cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colorectal cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on colorectal cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for colorectal cancer

181. The predictive effect of primary tumour location in the treatment of metastatic colorectal cancer: a Canadian consensus statement

. Arai T, Kino I. Morphometrical and cell kinetic studies of normal human colorectal mucosa. Comparison between the proximal and the distal large intestine. Acta Pathol Jpn 1989;39:725–30. 7. Bara J, Nardelli J, Gadenne C, Prade M, Burtin P. Differences in the expression of mucus-associated antigens between proximal and distal human colon adenocarcinomas. Br J Cancer 1984;49:495–501. 8. Soong R, Powell B, Elsaleh H, et al. Prognostic significance of TP53 gene mutation in 995 cases of colorectal (...) . Dis Colon Rectum 2007;50:1783–99. 3. Bufill JA. Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. Ann Intern Med 1990;113:779–88. 4. Rothberg PG, Spandorfer JM, Erisman MD, et al. Evidence that c-Myc expression defines two genetically distinct forms of colorectal adenocarcinoma. Br J Cancer 1985;52:629–32. 5. Delattre O, Olschwang S, Law DJ, et al. Multiple genetic alterations in distal and proximal colorectal cancer. Lancet 1989;2:353–6. 6

2018 CPG Infobase

182. Selective internal radiation therapy for chemotherapy refractory intolerant metastatic colorectal cancer

Selective internal radiation therapy for chemotherapy refractory intolerant metastatic colorectal cancer NHS England » Selective internal radiation therapy for chemotherapy refractory intolerant metastatic colorectal cancer Search Search Menu Selective internal radiation therapy for chemotherapy refractory intolerant metastatic colorectal cancer Document first published: 28 December 2018 Page updated: 28 December 2018 Topic: Publication type: , NHS England will commission selective internal (...) radiation therapy (SIRT) for chemotherapy refractory / intolerant metastatic colorectal cancer in adults in accordance with the criteria outlined in this document. In creating this policy NHS England has reviewed this clinical condition and the options for its treatment. It has considered the place of this treatment in current clinical practice, whether scientific research has shown the treatment to be of benefit to patients, (including how any benefit is balanced against possible risks) and whether its

2018 NHS England

183. Colorectal cancer screening in persons with a relevant family history - Update to commission S11-01

in Health Care (IQWiG) - ii - IQWiG employees ? Mareike Kracht ? Tatjana Hermanns ? Julia Kreis ? Fabian Lotz ? Christoph Mosch ? Ulrike Paschen Keywords: Early Detection of Cancer, Mass Screening, Colorectal Neoplasms, Family History, Benefit Assessment, Systematic Review Extract of rapid report S17-01 Version 1.0 Colorectal cancer screening in persons with a family history – update 24 April 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - iii - Key statement Research question (...) Colorectal cancer screening in persons with a relevant family history - Update to commission S11-01 1 Translation of the key statement of the rapid report S17-01 Darmkrebsfrüherkennung bei Personen unter 55 Jahren mit familiärem Risiko – Aktualisierung (Version 1.0; Status: 24 April 2018). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

184. In colonic ρ0 (rho0) cells reduced mitochondrial function mediates transcriptomic alterations associated with cancer Full Text available with Trip Pro

approach to identify their changes linked to cancer pathobiology.Human colon cancer HCT116 cells, control and ρ0, were used for qPCR. Bioinformatics analysis: GeneCards, Kaplan-Meier Survival, GENT, cBioPortal.The colonic ρ0 transcriptome was linked with proliferation, DNA replication, survival, tumor morphology, and cancer. Among differentially expressed transcripts, 281 were regulators or biomarkers of human colon cancer especially those with inflammatory microsatellite instability (MSI). We (...) In colonic ρ0 (rho0) cells reduced mitochondrial function mediates transcriptomic alterations associated with cancer Mitochondrial reprogramming has emerged as a hallmark of cancer pathobiology. Although it is believed this reprogramming is essential for cancer cells to thrive, how it supports cancer pathobiology is unclear. We previously generated colonic ρ0 (rho0) cells with reduced mitochondrial energy function and acquired their transcriptional signature. Here, we utilized a bioinformatics

2017 Oncoscience

185. Rare gastrointestinal stromal tumors (GIST): omentum and retroperitoneum Full Text available with Trip Pro

Rare gastrointestinal stromal tumors (GIST): omentum and retroperitoneum Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms that arise in the gastrointestinal tract and rarely elsewhere in the abdomen. GISTs that develop outside the digestive tract are called extra-GISTs (EGISTs). The incidence of EGISTs is reported to be approximately 10% of all GISTs, and the median age is younger than that of conventional GISTs. EGISTs have similar histology (...) and immunohistochemical features as conventional GISTs, with the majority of them in the omentum and mesentery. Most GISTs harbor a kinase-activating mutation in either KIT or PDGFRA. For EGISTs, the incidence of this type of mutation is 40-50%, which is somewhat lower than for conventional GISTs. EGISTs may have a worse prognosis compared with conventional GISTs with high mitotic indices, large size, and distant metastasis including lymph node involvement. In large abdominal tumors, the visceral origin is almost

2017 Translational gastroenterology and hepatology

186. Endoscopic resection of gastric gastrointestinal stromal tumors Full Text available with Trip Pro

Endoscopic resection of gastric gastrointestinal stromal tumors Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors in the gastrointestinal tract, and about 60% of them are found in the stomach. With the widespread application of endoscopy and endoscopic ultrasonography (EUS), more and more gastric GISTs are being found in an early stage (with a relative small diameter and no metastasis), giving the chance of complete resection. Endoscopic resection such as endoscopic

2017 Translational gastroenterology and hepatology

187. An E-Learning Module to Improve Nongenetic Health Professionals’ Assessment of Colorectal Cancer Genetic Risk: Feasibility Study Full Text available with Trip Pro

An E-Learning Module to Improve Nongenetic Health Professionals’ Assessment of Colorectal Cancer Genetic Risk: Feasibility Study Nongenetic health providers may lack the relevant knowledge, experience, and communication skills to adequately detect familial colorectal cancer (CRC), despite a positive attitude toward the assessment of history of cancer in a family. Specific training may enable them to more optimally refer patients to genetic counseling.The aim of this study was to develop an e (...) module to help surgeons-in-training and gastroenterologists in recognizing a hereditary predisposition in patients with CRC. The e-learning led to improvements in attitude toward the assessment of cancer family history, knowledge on criteria for referral to genetic counseling for CRC, and comprehension of communication skills.©Kirsten Freya Lea Douma, Cora M Aalfs, Evelien Dekker, Pieter J Tanis, Ellen M Smets. Originally published in JMIR Medical Education (http://mededu.jmir.org), 18.12.2017.

2017 JMIR medical education

188. Erbitux for Left Sided Metastatic Colorectal Cancer – Details

Erbitux for Left Sided Metastatic Colorectal Cancer – Details Erbitux for Left Sided Metastatic Colorectal Cancer – Details | CADTH.ca Find the information you need Erbitux for Left Sided Metastatic Colorectal Cancer – Details Erbitux for Left Sided Metastatic Colorectal Cancer – Details Project Number pCODR 10128 Brand Name Erbitux Generic Name Cetuximab Strength 2 mg/mL Tumour Type Gastrointestinal Indication Left Sided Metastatic Colorectal Cancer Funding Request For the first-line treatment (...) of RAS wild-type metastatic colorectalcarcinoma (mCRC) patients with left sided primary tumours Review Status File-Closed Not Submitted Clarification The submitter notified pCODR that they will not be filing the submission. Pre Noc Submission No NOC Date September 9, 2005 Manufacturer Eli Lilly Canada Inc. Submitter Eli Lilly Canada Inc. Submission Date (Target Date) Submission Type New Indication Prioritization Requested Stakeholder Input Deadline (target date based on target submission date

2017 CADTH - Pan Canadian Oncology Drug Review

189. Minimally invasive surgery for gastric gastrointestinal stromal tumors Full Text available with Trip Pro

Minimally invasive surgery for gastric gastrointestinal stromal tumors Minimally invasive surgery has been increasingly performed for gastric gastrointestinal stromal tumors (GIST). In this review we discuss and summarize the current evidence on minimally invasive surgery for gastric GISTs. Laparoscopic resection for gastric GIST has been consistently shown to be associated with superior perioperative outcomes with no compromise in oncological outcomes when compared to open resection (...) in numerous retrospective case-control studies. It has also been shown to be safe and feasible for large tumors or tumors located in unfavorable sites. However, to date, there remains a lack of level 1 evidence from prospective randomized control trials in support of laparoscopic resection.

2017 Translational gastroenterology and hepatology

190. Initial clinical experience using a novel Pd-103 surface applicator for the treatment of retroperitoneal and abdominal wall malignancies Full Text available with Trip Pro

Initial clinical experience using a novel Pd-103 surface applicator for the treatment of retroperitoneal and abdominal wall malignancies 29904748 2019 02 26 2452-1094 3 2 2018 Apr-Jun Advances in radiation oncology Adv Radiat Oncol Initial clinical experience using a novel Pd-103 surface applicator for the treatment of retroperitoneal and abdominal wall malignancies. 216-220 10.1016/j.adro.2017.11.005 Zhen Heming H Department of Radiation Oncology, Boston Medical Center, Boston, Massachusetts

2017 Advances in radiation oncology

191. Surgical treatment of gastrointestinal stromal tumors of the stomach: current status and future perspective Full Text available with Trip Pro

Surgical treatment of gastrointestinal stromal tumors of the stomach: current status and future perspective Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract, with the majority found in the stomach. Surgical resection of the primary gastric GISTs with complete resection margin has been the forefront of curative treatment. The indications for surgical resection are usually related to symptomatic gastric GISTs at presentation. Primary (...) factors (size and mitotic index), patient factors (older age, male) and surgical factors (incomplete resection margin, tumor rupture or spillage) play an important role in stratifying the malignant potential risk of primary gastric GISTs and their chances of recurrence. The understanding of gene mutation driving the growth of GISTs and the discovery of tyrosine kinase inhibitors (TKIs) has altered the surgical management of advanced and metastatic GISTs. Multi-modal therapy incorporating the surgical

2017 Translational gastroenterology and hepatology

192. Experience with an abdominal compression band for radiotherapy of upper abdominal tumours Full Text available with Trip Pro

Experience with an abdominal compression band for radiotherapy of upper abdominal tumours Radiotherapy outcomes are influenced by treatment delivery geometric accuracy and organ-at-risk dose. The location of abdominal structures such as the liver, kidneys and tumour volumes can be strongly influenced by respiratory motion. This increases geometric uncertainty and dose to organs-at-risk. One common method of minimising respiratory motion is abdominal compression (AC).Fifteen patients being (...) treated for radiotherapy to upper abdominal tumours were analysed. Each patient underwent 2 four-dimensional computerised tomography (4D-CT) scans, one with and one without AC with a pneumatic compression belt. Liver and kidney positions were measured on the 4DCT scans at the peak inspiratory and expiratory respiratory phases. The patient received radiation therapy treatment planned on the CT data set with the technique (compression or no compression) that provided the least respiratory motion.There

2017 Journal of medical radiation sciences

193. The proof is in the pudding: improving adenoma detection rates reduces interval colon cancer development Full Text available with Trip Pro

The proof is in the pudding: improving adenoma detection rates reduces interval colon cancer development 29264437 2018 11 13 2415-1289 2 2017 Translational gastroenterology and hepatology Transl Gastroenterol Hepatol The proof is in the pudding: improving adenoma detection rates reduces interval colon cancer development. 99 10.21037/tgh.2017.11.10 Umar Sarah B SB Division of Gastroenterology and Hepatology, Mayo Clinic, Arizona, USA. Ramirez Francisco C FC Division of Gastroenterology

2017 Translational gastroenterology and hepatology

194. Randomized clinical trial of laparoscopic ultrasonography before laparoscopic colorectal cancer resection (Abstract)

Randomized clinical trial of laparoscopic ultrasonography before laparoscopic colorectal cancer resection Intraoperative ultrasonography during open surgery for colorectal cancer may be useful for the detection of unrecognized liver metastases. Laparoscopic ultrasonography (LUS) for the detection of unrecognized liver metastasis has not been studied in a randomized trial. This RCT tested the hypothesis that LUS would change the TNM stage and treatment strategy.Patients with colorectal cancer (...) of colorectal cancer is not recommended. Registration number: NCT02079389 (http://www.clinicaltrials.gov).© 2017 BJS Society Ltd Published by John Wiley & Sons Ltd.

2017 EvidenceUpdates

195. Bevacizumab (Kyomarc) - for the treatment of cancer of the colon or rectum, breast cancer, non-small cell lung cancer (NSCLC), kidney cancer, cervical cancer, and cancer of the ovary, the fallopian tube, or the peritoneum.

Bevacizumab (Kyomarc) - for the treatment of cancer of the colon or rectum, breast cancer, non-small cell lung cancer (NSCLC), kidney cancer, cervical cancer, and cancer of the ovary, the fallopian tube, or the peritoneum.

2017 European Medicines Agency - EPARs

196. Colorectal Cancer Awareness: The Gastroenterology Resolution for the Future Full Text available with Trip Pro

Colorectal Cancer Awareness: The Gastroenterology Resolution for the Future 29662926 2018 11 14 2341-4545 25 2 2018 Mar GE Portuguese journal of gastroenterology GE Port J Gastroenterol Colorectal Cancer Awareness: The Gastroenterology Resolution for the Future. 55-56 10.1159/000481861 Oliveira Ferreira Alexandre A Gastroenterology Department, Hospital Beatriz Ângelo, Loures, Portugal. eng Editorial 2017 11 30 Switzerland GE Port J Gastroenterol 101685861 2387-1954 Adenoma Colorectal cancer (...) Screening 2017 09 21 2017 09 27 2018 4 18 6 0 2018 4 18 6 0 2018 4 18 6 1 ppublish 29662926 10.1159/000481861 pjg-0025-0055 PMC5892355 Int J Cancer. 2015 Mar 1;136(5):E359-86 25220842 Cochrane Database Syst Rev. 2007 Jan 24;(1):CD001216 17253456 Gastroenterology. 2017 Jul;153(1):307-323 28600072 N Engl J Med. 2013 Sep 19;369(12):1095-105 24047059 JAMA. 2000 Oct 18;284(15):1954-61 11035892 N Engl J Med. 2014 Apr 3;370(14):1298-306 24693890

2017 GE Portuguese journal of gastroenterology

197. QTWiST analysis of the RECOURSE trial of trifluridine/tipiracil in metastatic colorectal cancer Full Text available with Trip Pro

QTWiST analysis of the RECOURSE trial of trifluridine/tipiracil in metastatic colorectal cancer A Quality-adjusted Time WIthout Symptoms of disease or Toxicity (QTWiST) analysis was carried out to assess quality-adjusted survival time in the RECOURSE trial of trifluridine/tipiracil versus placebo in pretreated metastatic colorectal cancer (mCRC).Duration of overall survival in the RECOURSE trial (n=798 patients) was partitioned into three discrete health states: toxicity (TOX), time without (...) . A sensitivity analysis using large variations in utility coefficients for TOX and REL produced a range of only approximately 0.5 months from minimum to maximum QTWiST.Quality-adjusted survival, as measured by QTWiST, shows clinically meaningful improvements in patients treated with trifluridine/tipiracil versus placebo in pretreated mCRC.

2017 ESMO open Controlled trial quality: uncertain

198. Proxies of quality of life in metastatic colorectal cancer: analyses in the RECOURSE trial Full Text available with Trip Pro

Proxies of quality of life in metastatic colorectal cancer: analyses in the RECOURSE trial In the pivotal phase III, randomised, double-blind, placebo-controlled RECOURSE study, treatment with trifluridine/tipiracil was well tolerated and associated with prolonged progression-free and overall survival in patients with metastatic colorectal cancer (mCRC). There was no formal analysis of quality of life (QoL) in RECOURSE. The aim of the present analysis was to assess proxies of QoL during

2017 ESMO open Controlled trial quality: predicted high

199. Novel Stool-Based Protein Biomarkers for Improved Colorectal Cancer Screening: A Case-Control Study. (Abstract)

Novel Stool-Based Protein Biomarkers for Improved Colorectal Cancer Screening: A Case-Control Study. The fecal immunochemical test (FIT) for detecting hemoglobin is used widely for noninvasive colorectal cancer (CRC) screening, but its sensitivity leaves room for improvement.To identify novel protein biomarkers in stool that outperform or complement hemoglobin in detecting CRC and advanced adenomas.Case-control study.Colonoscopy-controlled referral population from several centers.315 stool (...) samples from one series of 12 patients with CRC and 10 persons without colorectal neoplasia (control samples) and a second series of 81 patients with CRC, 40 with advanced adenomas, and 43 with nonadvanced adenomas, as well as 129 persons without colorectal neoplasia (control samples); 72 FIT samples from a third independent series of 14 patients with CRC, 16 with advanced adenomas, and 18 with nonadvanced adenomas, as well as 24 persons without colorectal neoplasia (control samples).Stool samples

2017 Annals of Internal Medicine

200. Pediatric gastrointestinal stromal tumors: a commentary on the value of referral clinics for rare pediatric tumors Full Text available with Trip Pro

Pediatric gastrointestinal stromal tumors: a commentary on the value of referral clinics for rare pediatric tumors 29264434 2018 11 13 2415-1289 2 2017 Translational gastroenterology and hepatology Transl Gastroenterol Hepatol Pediatric gastrointestinal stromal tumors: a commentary on the value of referral clinics for rare pediatric tumors. 96 10.21037/tgh.2017.11.01 Fernandez-Pineda Israel I Department of Surgery, St Jude Children's Research Hospital, Memphis, TN, USA. Rao Bhaskar N BN (...) 5:v98-102 20555113 Cancer. 2004 Jul 1;101(1):39-50 15221987 Ann Oncol. 2012 Oct;23 Suppl 7:vii49-55 22997454 Am J Surg Pathol. 2005 Oct;29(10):1373-81 16160481 Pediatr Blood Cancer. 2004 Feb;42(2):186-9 14752885 J Clin Oncol. 2017 Feb 10;35(5):523-528 28029307

2017 Translational gastroenterology and hepatology